# AngioSlide

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/angioslide

- Industry: Medical Devices & Equipment
- Headquarters: Netanya, Israel
- Website: www.angioslide.com
- Total disclosed funding: $15M
- Latest round: Series C (Jan 3, 2013)
- Investors on record: 6

## About

AngioSlide Ltd. develops innovative medical devices designed to enhance vascular procedures through improved visualization and ease of use during surgeries.Founded in 2005, AngioSlide Ltd. is based in Netanya, Israel, and specializes in medical technology for vascular applications. In January 2013, the company raised USD 6.3 mn in Series C funding led by Triventures, with participation from Agate Medical Investments, BioStar Capital, Viola Group, and XT Investments. The company has completed a total of 6 deals since its inception.AngioSlide Ltd. focuses on delivering cutting-edge solutions for vascular procedures, aiming to simplify surgical processes and improve outcomes. Their flagship product line includes advanced imaging tools and devices that assist healthcare professionals in performing intricate vascular interventions with greater precision and safety. Their technology is primarily targeted at hospitals and surgical centers, facilitating enhanced procedural efficiency and patient care.AngioSlide Ltd. generates revenue through direct sales of its medical devices to healthcare institutions, alongside offering training and support services for product integration. Revenue streams are bolstered by strategic partnerships with healthcare providers, enabling broader access to their innovative solutions across various medical environments.AngioSlide Ltd. plans to utilize its latest funding of USD 6.3 mn from the Series C round to expand its market presence in the United States. The company aims to improve its existing product offerings and validate its technology across additional vascular beds. These initiatives are expected to enhance the company’s competitive positioning and drive future growth in key international markets.

## Funding rounds

- Series C, Jan 3, 2013, $6.3M — BioStar Capital, Viola Group, Agate Medical Investments, XT Investments, Triventures
- Series C, Jun 1, 2008, $8.6M — Viola Group, ITOCHU Technology Ventures, XT Investments

## Investors

- Viola Group (https://capitalatlas.ai/funds/viola-group) — Series C
- ITOCHU Technology Ventures (https://capitalatlas.ai/funds/itochu-technology-ventures) — Series C
- XT Investments (https://capitalatlas.ai/funds/xt-investments) — Series C
- BioStar Capital (https://capitalatlas.ai/funds/biostar-capital) — Series C
- Agate Medical Investments (https://capitalatlas.ai/funds/agate-medical-investments) — Series C
- Triventures (https://capitalatlas.ai/funds/triventures) — Series C